Patients in the DEP and corresponding DLTs (dose escalation set)
| Duvelisib dose . | Patient no. . | Disease subtype . | DLT . |
|---|---|---|---|
| 8 mg BID | 1 | RR CLL/SLL | — |
| 15 mg BID | 2 | RR CLL/SLL | Grade 4 neutropenia |
| 3 | iNHL | — | |
| 4 | MM | — | |
| 5 | aNHL | — | |
| 6 | MM | — | |
| 7 | RR CLL/SLL | — | |
| 25 mg BID | 8 | iNHL | — |
| 9 | aNHL | — | |
| 10 | RR CLL/SLL | — | |
| 11 | MCL | — | |
| 12 | TCL | — | |
| 13 | RR CLL/SLL | — | |
| 14 | iNHL | — | |
| 35 mg BID | 15 | HL | — |
| 16 | aNHL | — | |
| 17 | MM | — | |
| 50 mg BID | 18 | iNHL | — |
| 19 | TCL | — | |
| 20 | HL | — | |
| 60 mg BID | 21 | TCL | — |
| 22 | TCL | — | |
| 23 | TCL | — | |
| 75 mg BID | 24 | aNHL | — |
| 25 | TCL | — | |
| 26 | TCL | Grade 3 cellulitis | |
| 27 | HL | — | |
| 28 | aNHL | — | |
| 29 | aNHL | — | |
| 100 mg BID | 30 | aNHL | Grade 3 ALT elevation |
| Grade 3 AST elevation | |||
| 31 | TCL | Grade 3 rash (maculopapular) |
| Duvelisib dose . | Patient no. . | Disease subtype . | DLT . |
|---|---|---|---|
| 8 mg BID | 1 | RR CLL/SLL | — |
| 15 mg BID | 2 | RR CLL/SLL | Grade 4 neutropenia |
| 3 | iNHL | — | |
| 4 | MM | — | |
| 5 | aNHL | — | |
| 6 | MM | — | |
| 7 | RR CLL/SLL | — | |
| 25 mg BID | 8 | iNHL | — |
| 9 | aNHL | — | |
| 10 | RR CLL/SLL | — | |
| 11 | MCL | — | |
| 12 | TCL | — | |
| 13 | RR CLL/SLL | — | |
| 14 | iNHL | — | |
| 35 mg BID | 15 | HL | — |
| 16 | aNHL | — | |
| 17 | MM | — | |
| 50 mg BID | 18 | iNHL | — |
| 19 | TCL | — | |
| 20 | HL | — | |
| 60 mg BID | 21 | TCL | — |
| 22 | TCL | — | |
| 23 | TCL | — | |
| 75 mg BID | 24 | aNHL | — |
| 25 | TCL | — | |
| 26 | TCL | Grade 3 cellulitis | |
| 27 | HL | — | |
| 28 | aNHL | — | |
| 29 | aNHL | — | |
| 100 mg BID | 30 | aNHL | Grade 3 ALT elevation |
| Grade 3 AST elevation | |||
| 31 | TCL | Grade 3 rash (maculopapular) |
AEs were coded using Medical Dictionary for Regulatory Activities, version 16.1, and were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.
MM = multiple myeloma.
*Patient number represents the order in which patients were enrolled in the study.